Table 1 Independent cohorts used for the discovery, evaluation, and validation of biomarkers
Discovery cohort n = 280 | Biomarker evaluation cohort n = 48 | Model validation cohort n = 105 | ||||
|---|---|---|---|---|---|---|
AN | NN | AN | NN | AN | NN | |
Total (n) | 150 | 130 | 27 | 21 | 66 | 39 |
Age median (range) | 62.0 (51–72) | 62.0 (51–72) | 62.5 (50–75) | 62.0 (51–75) | 63.5 (50–75) | 63.0 (50–72) |
Sex | ||||||
Male | 75 | 65 | 14 | 10 | 36 | 20 |
Female | 75 | 65 | 13 | 11 | 30 | 19 |
NCF | – | 30 | - | 7 | - | 15 |
BEN | – | 50 | - | 7 | - | 13 |
Hemorrhoids | – | 25 | - | 3 | - | 8 |
Diverticula | – | 25 | - | 4 | - | 5 |
NAA | – | 50 | - | 7 | - | 11 |
AA | 100 | – | 16 | – | 42 | – |
AA histology | – | |||||
TA (size > 10mm) | 52 | – | 11 | – | 24 | – |
TVA | 36 | – | 3 | – | 15 | – |
VA | 12 | 2 | – | 3 | – | |
AA dysplasia | ||||||
LGD | 96 | – | 13 | – | 36 | – |
HGD | 4 | – | 3 | – | 7 | – |
AA localization | ||||||
Distal | 50 | – | 8 | – | 23 | – |
Proximal | 50 | – | 8 | – | 19 | – |
CRC | 50 | – | 11 | – | 24 | – |
CRC AJCC stage | ||||||
Stage I | 16 | – | 3 | – | 8 | – |
Stage II | 14 | – | 3 | – | 8 | – |
Stage III | 14 | – | 4 | – | 2 | – |
Stage IV | 6 | – | 1 | – | 6 | – |
CRC localization | ||||||
Distal | 39 | – | 9 | – | 12 | – |
Proximal | 11 | – | 2 | – | 12 | – |